Metabolism considerations for kinase inhibitors in cancer treatment

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 10, 2010, Pages 1175-1193

  Duckett, Derek R ^a   Cameron, Michael D ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Bioactivation; Dasatinib; Drug metabolism; Drug toxicity; Erlotinib; Gefitinib; Imatinib; Lapatinib; Nilotinib; Sorafenib; Sunitinib; Tyrosine kinase

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBAMAZEPINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOTOXIC AGENT; DASATINIB; DEXTROMETHORPHAN; DICLOFENAC; DIHYDRALAZINE; ERLOTINIB; GEFITINIB; IMATINIB; INTERFERON; KETOCONAZOLE; LAPATINIB; MIDAZOLAM; NILOTINIB; PHOSPHOTRANSFERASE INHIBITOR; RIFAMPICIN; SIMVASTATIN; SORAFENIB; SUNITINIB; TIENILIC ACID; TOPOTECAN; UNINDEXED DRUG; VINCRISTINE;

ACUTE HEPATITIS; ANEMIA; ANOREXIA; BLOOD TOXICITY; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER THERAPY; CARDIOVASCULAR DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COVALENT BOND; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG COMPETITION; DRUG CYTOTOXICITY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; DRUG TRANSPORT; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HAND FOOT SYNDROME; HUMAN; HYDROPHOBICITY; HYPERTENSION; INTERSTITIAL LUNG DISEASE; ISOTOPE LABELING; KIDNEY CARCINOMA; LEUKEMIA; LIVER MICROSOME; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PANCREAS CARCINOMA; PROTEIN EXPRESSION; QT INTERVAL; REVIEW; SIDE EFFECT; SKIN TOXICITY; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; TOXIC HEPATITIS; UNSPECIFIED SIDE EFFECT; UPREGULATION; WOUND HEALING IMPAIRMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG INTERACTIONS; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS;

EID: 77956868186     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2010.506873     Document Type: Review

References (123)

1. de Klein A, van Kessel AG, Grosveld G, et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982;300:765-767
2. Shtivelman E, Lifshitz B, Gale RP, et al. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985;315:550-554
3. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004;103:4010-4022
4. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037
5. Druker BJ, Guilhot F, OBrien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-2417
6. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005;105:2640-2653
7. OBrien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004
8. Peng B, Dutreix C, Mehring G, et al. Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol 2004;44:158-162
9. Bolton AE, Peng B, Hubert M, et al. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 2004;53:102-106
10. Dutreix C, Peng B, Mehring G, et al. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol 2004;54:290-294 (Pubitemid 39304422)
11. OBrien SG, Meinhardt P, Bond E, et al. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer 2003;89:1855-1859
12. Kil KE, Ding YS, Lin KS, et al. Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec). Nucl Med Biol 2007;34:153-163
13. Breedveld P, Pluim D, Cipriani G, et al. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 2005;65:2577-2582
14. White DL, Saunders VA, Dang P, et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006;108:697-704
15. White DL, Saunders VA, Dang P, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007;110:4064-4072
16. Crossman LC, Druker BJ, Deininger MW, et al. hOCT 1 and resistance to imatinib. Blood 2005;106:1133-1134; author reply 1134
17. Soverini S, Colarossi S, Gnani A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006;12:7374-7379
18. Davies A, Jordanides NE, Giannoudis A, et al. Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia 2009;23(11):1999-2006
19. European Medicines Agency. 2007 Tasigna, INN-nilotinib, report H-798-en6. Available from: http://www.ema.europa.eu/humandocs/ PDFs/EPAR/tasigna/H-798- en6.pdf, Ed
20. Hazarika M, Jiang X, Liu Q, et al. Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res 2008;14:5325-5331
21. Yin OQ, Gallagher N, Tanaka C, et al. Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study. Clin Ther 2009;31(Pt 2):2459-2469
22. Owen A, Goldring C, Morgan P, et al. Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements. Br J Clin Pharmacol 2006;62:237-242
23. OHare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500-4505
24. Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26:127-132
25. Quintas-Cardama A, Kantarjian H, Jones D, et al. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 2007;109:497-499
26. Gambacorti-Passerini C, Gasser M, Ahmed S, et al. Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies. Leukemia 2005;19:1267-1269
27. Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007;109:5143-5150 (Pubitemid 46890528)
28. Bonvin A, Mesnil A, Nicolini FE, et al. Dasatinib-induced acute hepatitis. Leuk Lymphoma 2008;49(8):1630-1632
29. Rea D, Bergeron A, Fieschi C, et al. Dasatinib-induced lupus. Lancet 2008;372:713-714
30. Johnson FM, Agrawal S, Burris H, et al. Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer 2010;116:1582-1591
31. Li X, He Y, Ruiz CH, et al. Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways. Drug Metab Dispos 2009;37:1242-1250
32. Hiwase DK, Saunders V, Hewett D, et al. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res 2008;14:3881-3888
33. He K, Lago MW, Iyer RA, et al. Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats. Drug Metab Dispos 2008;36:2564-2570
34. Schapira D, Bassan L, Nahir AM, et al. Diclofenac-induced hepatotoxicity. Postgrad Med J 1986;62:63-65
35. Wu Y, Sanderson JP, Farrell J, et al. Activation of T cells by carbamazepine and carbamazepine metabolites. J Allergy Clin Immunol 2006;118:233-241
36. Moore NC, Lerer B, Meyendorff E, et al. Three cases of carbamazepine toxicity. Am J Psychiatry 1985;142:974-975
37. Homberg JC, Andre C, Abuaf N. A new anti-liver-kidney microsome antibody (anti-LKM2) in tienilic acid-induced hepatitis. Clin Exp Immunol 1984;55:561-570
38. Beaune PH, Lecoeur S, Bourdi M, et al. Anti-cytochrome P450 autoantibodies in drug-induced disease. Eur J Haematol Suppl 1996;60:89-92
39. Masubuchi Y, Horie T. Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs. Crit Rev Toxicol 2007;37:389-412
40. Siegel-Lakhai WS, Beijnen JH, Schellens JH. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). Oncologist 2005;10:579-589
41. Dudek AZ, Kmak KL, Koopmeiners J, et al. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. Lung Cancer 2006;51:89-96
42. Pascual JC, Belinchon I, Sivera F, et al. Severe cutaneous toxicity following treatment with gefitinib (ZD1839). Br J Dermatol 2005;153:1222-1223
43. Carlini P, Papaldo P, Fabi A, et al. Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450? J Clin Oncol 2006;24:e60-1
44. Yoshimoto A, Kasahara K, Kimura H, et al. Transient liver injury caused by gefitinib. Nihon Kokyuki Gakkai Zasshi 2004;42:56-61
45. Cohen MH, Williams GA, Sridhara R, et al. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003;8:303-306
46. Ieki R, Saitoh E, Shibuya M. Acute lung injury as a possible adverse drug reaction related to gefitinib. Eur Respir J 2003;22:179-181
47. Inomata S, Takahashi H, Nagata M, et al. Acute lung injury as an adverse event of gefitinib. Anticancer Drugs 2004;15:461-467
48. Kitajima H, Takahashi H, Harada K, et al. Gefitinib-induced interstitial lung disease showing improvement after cessation: disassociation of serum markers. Respirology 2006;11:217-220
49. Ohyanagi F, Ando Y, Nagashima F, et al. Acute gefitinib-induced pneumonitis. Int J Clin Oncol 2004;9:406-409
50. Shih YN, Chiu CH, Tsai CM, et al. Interstitial pneumonia during gefitinib treatment of non-small-cell lung cancer. J Chin Med Assoc 2005;68:183-186
51. Suzuki M, Asahina H, Konishi J, et al. Recurrent gefitinib-induced interstitial lung disease. Intern Med 2008;47:533-536
52. Takano T, Ohe Y, Kusumoto M, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 2004;45:93-104
53. Liu V, White DA, Zakowski MF, et al. Pulmonary toxicity associated with erlotinib. Chest 2007;132:1042-1044
54. Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003;361:137-139
55. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002;20:2240-2250
56. Swaisland HC, Smith RP, Laight A, et al. Single-dose clinical pharmacokinetic studies of gefitinib. Clin Pharmacokinet 2005;44:1165-1177
57. McKillop D, Hutchison M, Partridge EA, et al. Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man. Xenobiotica 2004;34:917-934 (Pubitemid 39648170)
58. McKillop D, McCormick AD, Miles GS, et al. In vitro metabolism of gefitinib in human liver microsomes. Xenobiotica 2004;34:983-1000
59. McKillop D, McCormick AD, Millar A, et al. Cytochrome P450-dependent metabolism of gefitinib. Xenobiotica 2005;35:39-50
60. Li J, Zhao M, He P, et al. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 2007;13:3731-3737
61. Li X, Kamenecka TM, Cameron MD. Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities. Chem Res Toxicol 2009;22:1736-1742
62. Su H, Seimbille Y, Ferl GZ, et al. Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. Eur J Nucl Med Mol Imaging 2008;35:1089-1099
63. Mogi M, Yang J, Lambert JF, et al. Akt signaling regulates side population cell phenotype via Bcrp1 translocation. J Biol Chem 2003;278:39068-39075
64. Nagashima S, Soda H, Oka M, et al. BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib 7in non-small cell lung cancer. Cancer Chemother Pharmacol 2006;58:594-600
65. Leggas M, Panetta JC, Zhuang Y, et al. Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Res 2006;66:4802-4807
66. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-1966
67. Tang PA, Tsao MS, Moore MJ. A review of erlotinib and its clinical use. Expert Opin Pharmacother 2006;7:177-193
68. Rudin CM, Liu W, Desai A, et al. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol 2008;26:1119-1127
69. Bovenschen HJ, Alkemade JA. Erlotinib-induced dermatologic side-effects. Int J Dermatol 2009;48:326-328
70. Chou LS, Garey J, Oishi K, et al. Managing dermatologic toxicities of epidermal growth factor receptor inhibitors. Clin Lung Cancer 2006;8(Suppl 1):S15-22
71. Lubbe J, Masouye I, Dietrich PY. Generalized xerotic dermatitis with neutrophilic spongiosis induced by erlotinib (Tarceva). Dermatology 2008;216:247-249
72. Liu W, Makrauer FL, Qamar AA, et al. Fulminant hepatic failure secondary to erlotinib. Clin Gastroenterol Hepatol 2007;5:917-920
73. Pellegrinotti M, Fimognari FL, Franco A, et al. Erlotinib-induced hepatitis complicated by fatal lactic acidosis in an elderly man with lung cancer. Ann Pharmacother 2009;43:542-545
74. Ramanarayanan J, Krishnan GS. Review: hepatotoxicity and EGFR inhibition. Clin Adv Hematol Oncol 2008;6:200-201
75. Ramanarayanan J, Scarpace SL. Acute drug induced hepatitis due to erlotinib. JOP 2007;8:39-43
76. Saif MW. Hepatic failure and hepatorenal syndrome secondary to erlotinib. Safety reminder. JOP 2008;9:748-752
77. Saif MW. Erlotinib-induced acute hepatitis in a patient with pancreatic cancer. Clin Adv Hematol Oncol 2008;6:191-199
78. OSI Pharmaceuticals, and Genentech. (2008) Important Safety Information. Available from: http://www.fda.gov/ downloads/Safety/MedWatch/ SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ UCM135238.pdf
79. Wacker B, Nagrani T, Weinberg J, et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007;13:3913-3921
80. OSI Pharmaceuticals, and Genentech. 2009 Tarceva perscribing information
81. Ling J, Johnson KA, Miao Z, et al. Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab Dispos 2006;34:420-426
82. Hamilton M, Wolf JL, Rusk J, et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006;12:2166-2171
83. Li X, Kamenecka TM, Cameron MD. P450-mediated bioactivation of the EGFR inhibitor erlotinib to a reactive electrophile. Drug Metab Dispos 2010;38(7):1238-1245
84. Marchetti S, de Vries NA, Buckle T, et al. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/-(triple-knockout) and wild-type mice. Mol Cancer Ther 2008;7:2280-2287
85. Rolff J, Dorn C, Merk J, et al. Response of patient-derived non-small cell lung cancer xenografts to classical and targeted therapies is not related to multidrug resistance markers. J Oncol 2009;2009:814140
86. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-2743
87. Wood ER, Truesdale AT, McDonald OB, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004;64:6652-6659
88. Burris HA III, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005;23:5305-5313
89. European Medicines Agency. 2008 Assessment report for Tyverb. Doc. Ref.: EMEA/302222/2008. Available from: http://www.emea.europa.eu
90. Ratain MJ, Cohen EE. The value meal: how to save $1,700 per month or more on lapatinib. J Clin Oncol 2007;25:3397-3398
91. Koch KM, Beelen AP, Ho PT, et al. The value of label recommendations: how to dose lapatinib. J Clin Oncol 2007;25:5331-2; author reply 5334-5335
92. Smith DA, Koch KM, Arya N, et al. Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2009;67:421-426
93. Polli JW, Humphreys JE, Harmon KA, et al. The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy] phenyl}-6-[5-({[2- (methylsulfonyl)ethy l] amino}methyl)-2-furyl]-4- quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos 2008;36:695-701
94. Dai CL, Tiwari AK, Wu CP, et al. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res 2008;68:7905-7914
95. Weil RJ, Palmieri DC, Bronder JL, et al. Breast cancer metastasis to the central nervous system. Am J Pathol 2005;167:913-920
96. Gril B, Palmieri D, Bronder JL, et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 2008;100:1092-1103
97. Bayer HealthCare Pharmaceuticals, Inc. NEXAVAR Prescribing Information; 2009
98. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009;6:465-477
99. European Medicines Agency. 2006 Nexavar, report H-690-en6. Available from: http://www.ema.europa. eu/humandocs/PDFs/EPAR/nexavar/ H-690-en6.pdf
100. Lathia C, Lettieri J, Cihon F, et al. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol 2006;57:685-692
101. Hu S, Chen Z, Franke R, et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res 2009;15:6062-6069
102. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-124
103. Motzer RJ, Michaelson MD, Rosenberg J, et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol 2007;178:1883-1887
104. Nishida T, Takahashi T, Nishitani A, et al. Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene. Int J Clin Oncol 2009;14:143-149
105. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-3590
106. van der Veldt AA, Boven E, Helgason HH, et al. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer 2008;99:259-265
107. Haznedar JO, Patyna S, Bello CL, et al. Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species. Cancer Chemother Pharmacol 2009;64:691-706
108. Parkinson A, Mudra DR, Johnson C, et al. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 2004;199:193-209
109. van Erp NP, Gelderblom H, Karlsson MO, et al. Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. Clin Cancer Res 2007;13:7394-7400
110. Zhou L, Meng F, Yin O, et al. Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients. Clin Ther 2009;31:1568-1575
111. Christopher LJ, Cui D, Wu C, et al. Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos 2008;36:1357-1364
112. Kim DW, Goh YT, Hsiao HH, et al. Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia. Int J Hematol 2009;89:664-672
113. Bergman E, Forsell P, Persson EM, et al. Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors. Int J Pharm 2007;341:134-142
114. Nakagawa K, Tamura T, Negoro S, et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 2003;14:922-930
115. Chu QS, Cianfrocca ME, Goldstein LJ, et al. A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer. Clin Cancer Res 2008;14:4484-4490
116. Britten CD, Kabbinavar F, Hecht JR, et al. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol 2008;61:515-524
117. Manley PW, Cowan-Jacob SW, Buchdunger E, et al. Imatinib: a selective tyrosine kinase inhibitor. Eur J Cancer 2002;38(Suppl 5):S19-27
118. Golemovic M, Verstovsek S, Giles F, et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res 2005;11:4941-4947
119. Kumar R, Crouthamel MC, Rominger DH, et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 2009;101:1717-1723
120. Wang L, Christopher LJ, Cui D, et al. Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos 2008;36:1828-1839
121. FDA. DASATINIB (BMS-354825) Oncologic Drug Advisory Committee Briefing Document-NDA 21-986; 2006
122. Swaisland HC, Ranson M, Smith RP, et al. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet 2005;44:1067-1081
123. European Medicines Agency. Sutent, report H-687en. Available from: http://www. ema.europa.eu/humandocs/PDFs/EPAR/ sutent/emea-combined-h687en.pdf